Effect of tezepelumab on seasonal exacerbations in patients with severe, uncontrolled asthma grouped by blood eosinophil count
J. Corren (Los Angeles, United States), A. Menzies-Gow (London, United Kingdom), C. Ambrose (Gaithersburg, United States), G. Colice (Gaithersburg, United States), S. Roseti (Gaithersburg, United States), Å. Hellqvist (Gothenburg, Sweden), K. Kmita (Warsaw, Poland), A. Lindsley (Thousand Oaks, United States), B. Cook (Gaithersburg, United States)
Source: International Congress 2022 – Clinical and translational studies of asthma and COPD: novel mechanisms
   
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Corren (Los Angeles, United States), A. Menzies-Gow (London, United Kingdom), C. Ambrose (Gaithersburg, United States), G. Colice (Gaithersburg, United States), S. Roseti (Gaithersburg, United States), Å. Hellqvist (Gothenburg, Sweden), K. Kmita (Warsaw, Poland), A. Lindsley (Thousand Oaks, United States), B. Cook (Gaithersburg, United States). Effect of tezepelumab on seasonal exacerbations in patients with severe, uncontrolled asthma grouped by blood eosinophil count. 2251
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|